News - EGFR L858R - LARVOL VERI

18h

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) (clinicaltrials.gov)

P1/2, N=200, Recruiting, Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Trial completion date: Dec 2029 --> Dec 2028 | Trial primary completion date: Dec 2028 --> Jun 2028

18 hours ago

Trial completion date • Trial primary completion date

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR exon 20 mutation

Tagrisso (osimertinib) • Zegfrovy (sunvozertinib)

18h

Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC. (PubMed, Front Mol Biosci)

Specifically, the mean OS was longer for patients with higher VAF in both the overall cohort and in subgroups with EGFR exon 19 deletions and exon 21 L858R mutations. These findings suggest that VAF could serve as a valuable predictive biomarker for treatment outcomes in EGFR-mutated NSCLC patients, highlighting its potential role in personalizing treatment strategies.

18 hours ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion

Tagrisso (osimertinib)

COCOON: Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (clinicaltrials.gov)

P2, N=305, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting

3 days ago

Enrollment closed • Adverse events

EGFR (Epidermal growth factor receptor)

EGFR L858R • EGFR exon 19 deletion

Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) • minocycline

WU-KONG36: Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II (clinicaltrials.gov)

P1/2, N=40, Recruiting, Sichuan University | Trial completion date: Feb 2026 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027

4 days ago

Trial completion date • Trial primary completion date

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L858R + EGFR exon 19 deletion

Zegfrovy (sunvozertinib)

Design, synthesis, and biological evaluation of novel probe-quality EGFR degraders targeting wild-type and Del19 mutation. (PubMed, Bioorg Med Chem Lett)

Physicochemical analysis indicated that PROTAC compounds exhibited cLogP and polar surface area (PSA) values closer to the ideal range, potentially contributing to their cellular permeability and degradation activity. In summary, this study represents a deepened and extended investigation built directly on previous seminal work, aiming to provide clearer guidance for the future development of allosteric EGFR degraders.

5 days ago

Journal

EGFR (Epidermal growth factor receptor) • CRBN (Cereblon)

EGFR mutation • EGFR L858R • EGFR T790M • EGFR wild-type

TROPION-Lung14: Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)

P3, N=582, Recruiting, AstraZeneca | Trial completion date: May 2032 --> Aug 2031

6 days ago

Trial completion date

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M

cobas® EGFR Mutation Test v2

Tagrisso (osimertinib) • Datroway (datopotamab deruxtecan-dlnk)

Leptomeningeal metastatic disease responding to carboplatin, pemetrexed, and amivantamab after progression to osimertinib in EGFR exon 21 L858R-Mutated non-small cell lung cancer: Two case reports. (PubMed, Respir Med Case Rep)

To our knowledge, this is the first report to demonstrate the efficacy of carboplatin, pemetrexed, and amivantamab against LMD progression after osimertinib therapy, suggesting that this regimen may be a therapeutic option for patients with LMD, including those with symptomatic disease. Nevertheless, further studies are warranted to confirm efficacy in this population.

6 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R

Tagrisso (osimertinib) • carboplatin • pemetrexed

Design, synthesis and biological evaluation of selective inhibitors against the L858R/T790 M/C797S mutant EGFR kinase based on the scaffold of brigatinib. (PubMed, Eur J Med Chem)

Furthermore, cell cycle arrest assay, apoptosis induction assays, Western blot assay, colony formation inhibition assay, cell migration inhibition assays, tube formation assay, and docking analysis were carried out to study the action mechanism of compound 8c. All these results indicated that compound 8c has the potential for further evaluation of in vivo efficacy and druggability.

6 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR T790M

Alunbrig (brigatinib)

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (clinicaltrials.gov)

P3, N=216, Active, not recruiting, AstraZeneca | Trial completion date: Apr 2027 --> Oct 2027

7 days ago

Trial completion date

EGFR mutation • EGFR L858R • EGFR exon 19 deletion

cobas® EGFR Mutation Test v2

Tagrisso (osimertinib)

BNT326-02: A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)

P1/2, N=420, Recruiting, BioNTech SE

7 days ago

Trial initiation date

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

KRAS mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • PD-L1 negative • RET mutation • MET mutation • EGFR negative

Keytruda (pembrolizumab) • carboplatin • paclitaxel • pumitamig (BNT327) • BNT326 • MK-3475 SC

Surgical management of the primary tumor in stage M1a-IVA Non-Small Cell Lung Cancer. (PubMed, J Thorac Cardiovasc Surg)

By comparing outcomes between patients managed with systemic therapy alone and those undergoing surgical intervention during treatment, this study suggests that primary tumor resection is feasible and may be associated with favorable survival outcomes in highly selected patients with stage M1a-IVA NSCLC.

8 days ago

Journal

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

EGFR L858R • EGFR exon 19 deletion • ALK fusion

Design, synthesis and biological evaluation of 2,4,5-trisubstituted 7H-Pyrrolo[2,3-d]pyrimidine derivatives as potent EGFR tyrosine kinase inhibitors against the C797S acquired resistance mutation. (PubMed, Bioorg Med Chem)

The C797S mutation in the epidermal growth factor receptor (EGFR) presents a significant challenge in treating non-small cell lung cancer (NSCLC), as it confers resistance to osimertinib...In vivo antitumor activity studies demonstrated that LN-B72 significantly inhibited tumor growth. This work establishes a promising foundation for developing novel therapeutic strategies targeting NSCLC patients with the C797S mutation.

9 days ago

Preclinical • Journal

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 20 insertion

Tagrisso (osimertinib)